Tetracycline

Should be taken on an empty stomach. Take on an empty stomach 1 hr before or 2 hr after meals w/ a full glass of water, in upright position. May be taken w/ meals to reduce GI discomfort.

Hypersensitivity to tetracyclines. Children <8 years. Severe renal impairment. Pregnancy and lactation. Concurrent use of methoxyflurane, retinoids or vitamin A.

Patient with myasthenia gravis, SLE. Children. Hepatic and mild to moderate renal impairment. Patient Counselling Avoid exposure to sunlight; wear protective clothing and use sunscreen. Use of eye ointment may cause transient blurring of vision and other eye disturbances, if affected, do not drive or operate machinery. Monitoring Parameters Monitor renal, hepatic and haematopoietic functions periodically; mental status. Obtain CBC and temperature. Assess culture and sensitivity prior to starting therapy.

Significant: Photosensitivity, intracranial hypertension, increased BUN. Enamel hypoplasia or permanent tooth discolouration in children, tissue hyperpigmentation in children <8 years. Blood and lymphatic system disorders: Rarely, agranulocytosis, aplastic or haemolytic anaemia, eosinophilia, neutropenia, thrombocytopenia. Gastrointestinal disorders: Oesophagitis, oesephageal ulceration, epigastric distress, glossitis, gastrointestinal irritations, dysphagia, nausea, vomiting, diarrhoea, abdominal discomfort, pancreatitis. Hepatobiliary disorders: Rarely, transient increases in LFT, hepatitis, hepatic failure, jaundice. Metabolism and nutrition disorders: Anorexia. Skin and subcutaneous tissue disorders: Erythematous or maculopapular rash, pruritus, bullous dermatoses, skin discolouration.
Potentially Fatal: Hypersensitivity reactions (e.g. anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, exacerbation of SLE). Clostridium difficile-associated disease (CDAD), hepatotoxicity.

Absorption may be impaired by divalent and trivalent cations (e.g. Al, Ca, Mg, Fe, Zn), Na bicarbonate, bismuth subsalicylate, kaolin-pectin, sucralfate, colestipol and colestyramine. May form a complex with strontium ranelate, resulting in decreased absorption of tetracycline. May interfere with the bactericidal action of penicillin. May prolong the effect of anticoagulants. May reduce plasma-atovaquone concentration. May decrease the efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients with diabetes mellitus. May increase the toxic effects of ergot alkaloids and methotrexate. May increase lithium and digoxin levels. May diminish therapeutic effects of BCG, BCG vaccine, typhoid vaccine.

Tetracyclines

D06AA04 - tetracycline ; Belongs to the class of topical tetracycline and derivatives agents used in the treatment of dermatological diseases.
S01AA09 - tetracycline ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
J01AA07 - tetracycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections.
S02AA08 - tetracycline ; Belongs to the class of antiinfectives used in the treatment of ear infections.
A01AB13 - tetracycline ; Belongs to the class of local antiinfective and antiseptic preparations. Used in the treatment of diseases of the mouth.
S03AA02 - tetracycline ; Belongs to the class of antiinfectives used in ophthalmologic and otologic preparations.